Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica

Acta Academiae Medicinae Sinica ›› 2015, Vol. 37 ›› Issue (5): 549-556.doi: 10.3881/j.issn.1000-503X.2015.05.010

• Orginal Article • Previous Articles     Next Articles

Prognostic Factors of Stage Ⅲ Colorectal Cancer in 433 Patients

De-cong SUN, Hui MAO, Zhi-kuan WANG, Yan SHI, Guang-hai DAI()   

  1. Second Department of Oncology,Chinese PLA General Hospital,Beijing 100853,China
  • Received:2014-10-16 Online:2015-10-15 Published:2015-10-31

Abstract:

Objective To summarize the prognostic factors of stage Ⅲ colorectal cancer. Methods The clinical data of 433 patients with stage Ⅲ colorectal cancer who were admitted to our hospital from January 2005 to December 2008 for radical surgery and adjuvant chemotherapy were retrospectively analyzed. Relationship of their clinicopathologic features and treatment with the prognosis were analyzed. Results Of these 433 stage Ⅲ patients,the mean disease-free survival was (72.37±2.11) months and mean overall survival was (79.91±2.02) months;however,the median survival times were not reached. The 1-,3-,and 5-year disease-free survival rate were 86.8%,77.9%,and 57.0% and the overall survival rate were 91.5%,75.1%,and 63.3%. Multivariate COX regression analysis displayed that intestine obstruction before surgery,complications after surgery,tumor location,positive surgical margin,neural cell infiltration,vessel cancer embolus,TNM stage,lymph node ratio,adjuvant chemotherapy regimens,and chemotherapy duration were the independent factors affecting disease-free and overall survivals in patients with stage Ⅲ colorectal cancer. The efficacies of FOLFOX and XELOX regimens were significantly correlated with patient’s age,complications,tumor location,and chemotherapy duration. Conclusions Complications,tumor location,TNM stage,and positive surgical margin are the independent prognostic factors of stage Ⅲ colorectal cancer. FOLFOX and XELOX regimen can remarkably improve prognosis,and a longer duration of chemotherapy can achieve better survival.

Key words: stage Ⅲ colorectal cancer, clinicalpathologic characters, adjuvant chemotherapy, prognosis

CLC Number: